Fruquintinib for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called fruquintinib for people with advanced colorectal cancer that has spread. It is for patients who have already tried several standard treatments and need a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have already tried standard treatments for colorectal cancer, including certain chemotherapies and targeted therapies.
- You have tried either trifluridine/tipiracil (Lonsurf) or regorafenib (Stivarga) and they no longer work or cause side effects you can't handle.
- You are not currently enrolled in another clinical trial (except follow-up).
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
This trial tests two drugs, fruquintinib and raltitrexed, for people with metastatic colorectal cancer that has stopped responding to or is no longer tolerable after standard treatments like fluorouracil, oxaliplatin, and irinotecan. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a drug called fruquintinib, given alone or with a chemotherapy infusion directly into your liver, for people whose colorectal cancer has spread to the liver and has stopped responding to standard treatments. It aims to find a new option for patients with limited cancer outside the liver.
This trial tests a combination of two oral chemotherapy drugs, fruquintinib and S-1, for people with metastatic colorectal cancer that has worsened after standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
This study follows adults in Poland who are receiving fruquintinib, a targeted cancer medicine, for advanced colorectal cancer that has spread. You would be enrolled if your doctor is already planning to give you fruquintinib as a later-line treatment after other therapies have stopped working.
Hear when a new Metastatic Colorectal Cancer (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.